Future research should concentrate on the main mechanisms of the role of immunomodulatory molecules such as TIGIT and CD161 in AML relapse in order to fully comprehend and maximize immunological reconstitution following bone marrow transplantation. The gene discussed is KLRB1; the disease is acute myeloid leukemia.